Zhang Jiani, Ren Yuxin, Li Bingjie, Cao Qi, Wang Xiaodong, Yu Haiyan
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.
Front Med (Lausanne). 2025 Feb 5;12:1489991. doi: 10.3389/fmed.2025.1489991. eCollection 2025.
Heart disease in pregnancy encompasses both congenital heart disease and maternal-acquired heart disease, both of which are associated with an increased risk of various adverse outcomes for mothers and their offspring.
The objective of the study was to review and summarize the evidence regarding the association between heart disease in pregnancy and adverse outcomes in mothers and their offspring.
A comprehensive search was conducted in Embase, PubMed, Web of Science, and the Cochrane Database of Systematic Reviews from inception to March 2024. The protocol for this review was registered in PROSPERO (CRD42024519144).
This review included systematic reviews and meta-analyses that examined the association between heart disease in pregnancy and adverse outcomes for mothers and their offspring.
Data were independently extracted by two reviewers. The quality of the systematic reviews and meta-analyses was assessed using the A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR2), while Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) was used to evaluate the strength of the evidence for each outcome.
A total of 12 meta-analyses and systematic reviews were included, which documented 156 adverse outcomes for mothers and 65 adverse outcomes for offspring. Evidence was found for both primary and secondary adverse outcomes. Adverse outcomes for mothers were death, cardiac events (cardiac arrest, heart failure, surgery, arrhythmia, anesthesia or sedation, endocarditis, mitral regurgitation, myocardial infarction, NYHA III-IV, restenosis, syncope, and others), pulmonary events (respiratory failure, pulmonary edema, and respiratory support), embolism, cerebrovascular events, postpartum hemorrhage, arterial events, delivery mode, and hospital stay. Adverse outcomes for offspring were death, pregnancy loss, growth restriction, low birth weight, preterm birth, recurrence, and uncertainty. No publication bias was detected using Egger's test. The overall AMSTAR 2 confidence rating for the included meta-analyses and systematic reviews was moderate. The majority (55.3%) of the evidence evaluated by GRADE was of low quality, while the remaining outcomes were categorized as having "very low"-quality evidence.
Current evidence links heart disease during pregnancy to adverse maternal outcomes, including death and cardiac, pulmonary, and cerebrovascular events, as well as increased mortality risk for offspring. Many meta-analyses in this field have limitations that raise concerns about their validity, highlighting the need for high-quality prospective studies.
妊娠合并心脏病包括先天性心脏病和母体获得性心脏病,这两种情况均与母亲及其后代出现各种不良结局的风险增加相关。
本研究的目的是回顾和总结关于妊娠合并心脏病与母亲及其后代不良结局之间关联的证据。
对Embase、PubMed、Web of Science以及Cochrane系统评价数据库进行了全面检索,检索时间从建库至2024年3月。本综述的方案已在PROSPERO(CRD42024519144)中注册。
本综述纳入了考察妊娠合并心脏病与母亲及其后代不良结局之间关联的系统评价和Meta分析。
由两名研究者独立提取数据。使用系统评价评估测量工具2(AMSTAR2)评估系统评价和Meta分析的质量,同时采用推荐分级、评估、制定与评价(GRADE)来评估每个结局的证据强度。
共纳入12项Meta分析和系统评价,记录了母亲的156项不良结局和后代的65项不良结局。发现了主要和次要不良结局的证据。母亲的不良结局包括死亡、心脏事件(心脏骤停、心力衰竭、手术、心律失常、麻醉或镇静、心内膜炎、二尖瓣反流、心肌梗死、纽约心脏协会心功能III-IV级、再狭窄、晕厥等)、肺部事件(呼吸衰竭、肺水肿和呼吸支持)、栓塞、脑血管事件、产后出血、动脉事件、分娩方式和住院时间。后代的不良结局包括死亡、妊娠丢失、生长受限、低出生体重、早产、复发和不确定性。使用Egger检验未检测到发表偏倚。纳入的Meta分析和系统评价的总体AMSTAR 2置信度评分为中等。GRADE评估的证据中,大多数(55.3%)质量较低,其余结局被归类为具有“极低”质量的证据。
目前的证据表明,妊娠期间的心脏病与母亲的不良结局相关,包括死亡以及心脏、肺部和脑血管事件,还与后代的死亡风险增加有关。该领域的许多Meta分析存在局限性,这引发了对其有效性的担忧,凸显了开展高质量前瞻性研究的必要性。